Table 4.
Patient #1 | Patient #2 | Patient #3 | ||
---|---|---|---|---|
Age | 63 | 67 | 63 | |
Surgery | Excision ALD | Excision ALD | Excision | |
ORS | 35 | 34 | 38 | |
RS using our formula | 15.57 | 17.6 | 15.2 | |
ER | IHC (Allred score) | 8 | 6 | 8 |
RT-PCR | Positive (8.5)* | Positive (11.1) | Positive (9.8) | |
PR | IHC (Allred score) | 6 | 4 | 0 |
RT-PCR | Positive (5.7) | Negative (3.2) | Negative (3.2) | |
Tumor size (mm) | 9 | 8 | 38 | |
Node status positive/total (N-stage) | 1/8 (1mi) | 1/3 (1mi) | 0/9 | |
Histology | IC NST | IC NST | ILC | |
Nottingham grade | II | II | III | |
TIL | 1 | 0 | 1 | |
Necrosis | 0 | 0 | 0 | |
Therapy | Chemotherapy | Cytoxan/Taxotere | None** | Cytoxan/Taxotere |
Hormonal therapy | Arimidex | Arimidex | Arimidex | |
Radiation therapy | Post excision | Post excision | Post excision | |
Survival | Alive and disease free (21 months) | Alive and disease free (24 months) | Bone metastases (28 months) Alive after 57 months |
Interpretation (ER Negative < 6.5, Positive ≥ 6.5; PR Negative < 5.5, Positive ≥ 5.5);
Declined chemotherapy;
ALD, axillary lymph node dissection; mi, micrometastases (>0.2-mm and <2-mm); IC NST, invasive carcinoma no special type; ILC, invasive lobular carcinoma; TIL, tumor infiltrating lymphocytes